All News
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met.
However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Dr. Rachel Tate uptoTate ( View Tweet)
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different? niche category for IL-17A and F use?
@RheumNow #RNL2023 https://t.co/dWkakahHAi
Robert B Chao, MD doctorRBC ( View Tweet)
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/ySk4hU5lMY
Eric Dein ericdeinmd ( View Tweet)
To differentiate mechanical from inflammatory lesion:
1-Site matters
2-Structural changes matter
Denis Poddubnyy #RNL2023 @RheumNow https://t.co/iQ1gHPnkqO
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases.
https://t.co/q3d6kNTVvo https://t.co/FBzZOMVlIK
Links:
Dr. John Cush RheumNow ( View Tweet)
PAISLEY: Deucravacitinib in SLE
#RNL2023 Year in Review
DEUC: oral TYK2i
P2, 48w DBRCT in active SLE
Primary endpt SRI4 at w32 - meets endpt, no dose response
Phase 3 study results needed, promising results but JAK studies failed for SLE
@RheumNow https://t.co/kKAKHnnG8i
Eric Dein ericdeinmd ( View Tweet)
AAV outcomes in patients with diffuse alveolar hemorrhage , @RheumNow Kavanaugh #RNL2023
I think i will still use it in sever patients. https://t.co/AEDH4diDuU
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2023 Year in Review
New Drugs in Old Disease?
GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb)
PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR)
@RheumNow https://t.co/cY2HuaI6uM
Eric Dein ericdeinmd ( View Tweet)
An exciting year and time for GCA and PMR treatment!
- Tocilizumab (IL-6i)
- Secukinumab (IL-17i)
- Sarilumab (IL-6i)
- Mavrilimumab (GM-CSF receptor mAb)
- Tofacitinib (JAKinib)
@RheumNow #RNL2023 https://t.co/d0T2RAssFY
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate uptoTate ( View Tweet)
Extension PEXIVAS study in ANCA vasculitis pts with severe DAH
- no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH
- note difference in curve
@RheumNow #RNL2023 https://t.co/6ktb3Uakw9
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilars back on the radar for 2023. Expect to see 17 in rheum. #RNL2023 @RheumNow https://t.co/SNYNM8nmD2
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar switching of Infliximab , @RheumNow Kavanaugh #RNL2023
Communications is a key always.
Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Will be begin using sputum instead of blood serologies to detect RA?
- sputum seropositive CCP may be associated with development of clinical RA
- 4 fold higher risk if (induced) sputum CCP+
@RheumNow #RNL2023 https://t.co/Z85GDwIyl8
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
Sputum antibody predicts future development of RA
Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA)
Strongest association with CCP IgA
Supports pre-RA as mucosal disease
@RheumNow https://t.co/Js4JPZiLDB
Eric Dein ericdeinmd ( View Tweet)
How does HCQ work
@Lupusreference in #RNL2023
HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN
HCQ works as base to increase lysosomal pH and affect cellular function
@RheumNow https://t.co/RTEUF0cS0u
Eric Dein ericdeinmd ( View Tweet)
@Lupusreference in #RNL2023
HCQ and arrhythmia via QTc prolongation
At normal doses, same as general population
If on other QTc prolonging medications, a baseline EKG may be beneficial
@RheumNow https://t.co/cAN2vBNa1t
Eric Dein ericdeinmd ( View Tweet)
Any dose more than 1500 is associated with retinopathy ? So what to do. @Lupusreference #RNL2023 @RheumNow https://t.co/2zdjpcuvKa
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Smoking and SLE
Smoking increases SLE activity
Smoking decreases HCQ efficacy
Skin response on HCQ down 50% in smokers 🚬
@Lupusreference #RNL2023 @RheumNow
Eric Dein ericdeinmd ( View Tweet)